Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials

Table 2

Presented at the 42nd Annual Fall Clinical Dermatology Conference | Las Vegas, NV | October 20–23, 2022

Objectives

To report long-term safety data, pooled to include three years of treatment, in patients with moderate to severe plaque psoriasis treated with bimekizumab (BKZ) across four phase 2 and four phase 3 clinical trials.

Introduction

- BKZ is a monoclonal immunoglobulin G1 antibody which selectively inhibits interleukin (IL)-17F in addition to IL-17A,^{1,2} and is used in the treatment of psoriasis.
- Given the chronic nature of psoriasis, it is important to consider long-term safety of treatments.³
- Data pooled over two years have indicated that BKZ is generally well-tolerated.4
- Here, the first three-year safety data for BKZ in patients with moderate to severe plaque psoriasis are reported, pooled from phase 2 and 3 clinical trials.

Materials and Methods

- Long-term safety data were evaluated for all patients who received ≥1 dose of BKZ in four phase 3 trials (BE SURE, BE VIVID, BE READY, and their ongoing open-label extension BE BRIGHT [data cut-off: 23 Oct 2021]) and four phase 2 trials (BE ABLE 1, BE ABLE 2, PS0016, and PS0018).⁵
- Safety data were also evaluated separately for patients receiving BKZ dosed 320 mg every 4 weeks (Q4W) or every 8 weeks (Q8W); Q8W dosing was only used in maintenance treatment in phase 3 trials, however, most patients were receiving BKZ Q8W by Year 3.
- Treatment-emergent adverse events (TEAEs) were coded using MedDRA v19.0. Data are presented cumulatively as exposure-adjusted incidence rates (EAIRs), defined as the incidence of new cases per 100 patient-years (PY).

Results

- Baseline demographics were similar between BKZ dose groups (Table 1).
- Safety data observed over three years of BKZ treatment were consistent with those observed over two years;⁴ EAIRs did not increase with longer BKZ exposure, and were generally lower in Q8W- vs Q4W-treated patients (Figure 1, Table 2).
- The three most common TEAEs in the phase 2/3 trials with BKZ were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with previous reports (Table 2).4
- Eighteen deaths occurred; all were deemed unrelated to BKZ except one (relationship unknown) at the time of the data cut-off.
- The rates of inflammatory bowel disease, adjudicated major adverse cardiac events, malignancies, adjudicated suicidal ideation and behavior, and neutropenia remained low, and were comparable to two-year data (Table 2).⁴ There were no cases of active tuberculosis.
- Rates of oral candidiasis decreased with longer duration of bimekizumab exposure (Figure 1C; Table 2). No serious oral candidiasis events occurred; the vast majority were mild or moderate (99.4%). Over three years of BKZ treatment, 79.9% of patients experienced no oral candidiasis events. Of those who did experience such events, most had either one (9.8%) or two (5.1%) occurrences.

Summary

		Phase 2 and 3 ^a		Phase 3 [♭]	
		BKZ Total	BKZ Q4W	BKZ Q8W	BKZ Total
6886	Population	N=1,789	N=1,456	N=1,289	N=1,495
0000	Exposure	4,245.3 PY	1,965.6 PY	1,914.5 PY	3,876.4 PY
6	Dosing	320 mg Q4W 320 mg Q8W 64 mg Q4W (phase 2) 160 mg Q4W (phase 2) 480 mg Q4W (phase 2)	320 mg Q4W	320 mg Q8W	320 mg Q4W 320 mg Q8W
	Trials administered	6 double-blinded trials and 2 OLEs	<mark>3</mark> double- blinded trials and	2 double- blinded trials and	3 double- blinded trials and

BKZ was well-tolerated over three years of treatment. Safety data were consistent with those observed over two years of BKZ treatment; no safety signals were identified.

The majority of patients were receiving BKZ Q8W by Year 3. Phase 2 and phase 3 data are pooled from the initial and maintenance treatment periods of the BE SURE BE VIVID and BE READY phase 3 trials, their oper label extension BE BRIGHT, and four phase 2 trials (BE ABLE 1, BE ABLE 2, PS0016, PS0018); Phase 3 data are pooled from the initial and maintenance treatment periods of the BE SURE, BE VIVID, and BE READY phase 3 trials, and their open-label extension BE BRIGHT

1 OLE

1 OLE

1 OLE

Table 1 Baseline characteristics

	Phase 2 and 3		Phase 3	
	BKZ Totalª (N=1,789)	BKZ 320 mg Q4W (N=1,456)	BKZ 320 mg Q8W (N=1,289)	BKZ Totalª (N=1,495)
Age (years) , mean <u>+</u> SD	45.2 <u>+</u> 13.5	45.4 <u>+</u> 13.5	45.5 <u>+</u> 13.3	45.4 <u>+</u> 13.4
Male, n (%)	1,252 (70.0)	1,042 (71.6)	934 (72.5)	1,067 (71.4)
Caucasian, n (%)	1,468 (82.1)	1,173 (80.6)	1,057 (82.0)	1,208 (80.8)
Region, n (%)			1	
North America	635 (35.5)	534 (36.7)	432 (33.5)	542 (36.3)
Central/Eastern Europe	728 (40.7)	535 (36.7)	528 (41.0)	558 (37.3)
Western Europe	168 (9.4)	164 (11.3)	144 (11.2)	168 (11.2)
Asia/Australia	258 (14.4)	223 (15.3)	185 (14.4)	227 (15.2)
Weight (kg), mean <u>+</u> SD	89.0 <u>+</u> 22.0	89.1 <u>+</u> 22.3	89.0 <u>+</u> 21.7	89.1 <u>+</u> 22.3
Disease duration (years), mean <u>+</u> SD	17.7 <u>+</u> 12.3	17.8 <u>+</u> 12.3	18.3 <u>+</u> 12.4	17.9 <u>+</u> 12.3
Prior biologic therapy, n (%)	636 (35.6)	559 (38.4)	508 (39.4)	576 (38.5)
Anti-TNF	240 (13.4)	200 (13.7)	180 (14.0)	207 (13.8)
Anti-IL-17	343 (19.2)	331 (22.7)	312 (24.2)	343 (22.9)
Prior systemic therapy, n (%)	1,360 (76.0)	1,135 (78.0)	1,019 (79.1)	1,166 (78.0)

Patients who received both BKZ 320 mg Q4W and Q8W are included in the population count of both treatment groups, but only once in each BKZ Total group

Milwaukee, Wisconsin, USA; ²Dalhousie University, Halifax, Nova Scotia, Canada; ³Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR I ine at Mount Sinai, New York, New York, USA; 7UCB Pharma, Raleigh, North Carolina, USA; 8UCB Pharma, Brussels, Belgium; 9UCB Pharma, Monheim, Germany

References: ¹Glatt S et al. Ann Rheum Dis 2018;77:523-32;²Adams R et al. Front Immunol 2020;11:1894; ³Warren RB et al. J Invest Dermatol 2015;135:2632-40; ⁴Gordon KB et al. JAMA Dermatol 2022;158(7);735-744; ⁵EE SURE (NCT03412947); BE VIVID (NCT03370133); BE READY (NCT03410992); BE BRIGHT (NCT03598790); BE ABLE 2 (NCT02905006); BE ABLE 2 (NCT03010527); PS0016 (NCT0325542); PS0018 (NCT03230292). Author Contributions: Substantial contributions to study conception/design, or acquisition/design, or investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, UCB Pharma; provided lectures for AbbVie, Amgen, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, and Pfizer. **RBW**: Received consulting fees from AbbVie, Almgen, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, and UCB Pharma; provided lectures for AbbVie, Almirall, Janssen, LEO Pharma, Nevartis, and UCB Pharma; received research grants to institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; Novartis, Pfizer, Sanofi, and UCB Pharma, Neverkis, and UCB Pharma, Neverkis, and UCB Pharma; Neverkis, and UCB Pharma; Neverkis, Pfizer, Sanofi, and UCB Pharma, Neverkis, Pfizer, Sanofi, and research grants from Eisai, Maruho, Shiseido, Torii; current consulting/advisory board agreements from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, UCB Pharma; clinical trials sponsored by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma; clinical trials sponsored by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Pfizer, Sun Pharma; clinical trials sponsored by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, and UCB Pharma, Dermira, Eli Lilly, Ianssen, Kyowa Kirin, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, UCB Pharma, UCB Pharma, UCB Pharma, Lilly, Ianssen, Kyowa Kirin, Novartis, Pfizer, and Regeneron; served as a paid speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Regeneron; served as a paid speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Regeneron; served as a paid speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Regeneron; served as a paid speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Regeneron; served as a paid speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, S Sanoti, N.L.: Employee of Mount Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regenerol, and the aperited is a part speaker of Abovie, Angen, Regeneron, and Lin, Verageutics, Regeneron, and Lin, Verageutics, Regeneron, and Lin, Verageutics, BionX, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, BiomX, Bo

Previously presented at EADV 2022

	TEAEs over two years ⁴	TEAEs over three years			
	Phase 2 and 3	Phase 2 and 3	Phase 3		
	BKZ Totalª (N=1,789)	BKZ Total ^a (N=1,789)	BKZ 320 mg Q4W (N=1,456)	BKZ 320 mg Q8W (N=1,289)	BKZ Totalª (N=1,495)
Summary of treatment exposure					
Total exposure, PY	3,109.7	4,245.3	1,965.6	1,914.5	3,876.4
Mean exposure <u>+</u> SD, days	608.5 <u>+</u> 232.6	837.0 <u>+</u> 365.7	476.2 <u>+</u> 284.4	536.5 <u>+</u> 290.8	932.4 <u>+</u> 317.7
Median exposure (range), days	673.0 (1–1,037)	995.0 (1–1,326)	504.0 (23–1,093)	448.0 (1–1,214)	1,058.0 (23–1,326)
Summary of TEAEs, EAIR/100 PY (95%)	CI)				
Any TEAE	202.4 (192.6, 212.6)	186.1 (177.2, 195.3)	217.9 (205.8, 230.5)	115.6 (108.2, 123.3)	175.5 (166.4, 185.0)
Severe TEAEs	5.4 (4.6, 6.3)	4.9 (4.3, 5.6)	5.3 (4.3, 6.4)	4.2 (3.3, 5.2)	4.5 (3.9, 5.3)
TEAEs leading to discontinuation	3.8 (3.1, 4.6)	3.5 (3.0, 4.1)	3.8 (2.9, 4.7)	2.5 (1.9, 3.3)	3.2 (2.6, 3.8)
Treatment-related TEAEs	35.4 (32.9, 38.0)	29.4 (27.4, 31.5)	42.3 (38.8, 45.9)	21.1 (18.8, 23.5)	28.9 (26.8, 31.1)
Serious TEAEs	5.9 (5.1, 6.9)	5.6 (4.9, 6.4)	6.2 (5.1, 7.4)	5.4 (4.4, 6.5)	5.5 (4.8, 6.4)
TEAEs leading to death	0.4 (0.2, 0.6)	0.4 (0.3, 0.7)	0.4 (0.2, 0.8)	0.4 (0.2, 0.8)	0.4 (0.2, 0.7)
Three most common TEAEs, EAIR/100	PY (95% CI)				
Nasopharyngitis	19.1 (17.4, 20.9)	15.3 (13.9, 16.7)	21.1 (18.9, 23.5)	10.0 (8.5, 11.6)	15.0 (13.6, 16.5)
Oral candidiasis	12.6 (11.3, 14.0)	10.2 (9.1, 11.3)	15.9 (14.1, 17.9)	7.1 (5.9, 8.5)	10.1 (9.1, 11.3)
Upper respiratory tract infection	8.9 (7.8, 10.1)	7.1 (6.2, 8.0)	8.9 (7.6, 10.4)	4.9 (3.9, 6.1)	6.5 (5.7, 7.4)
TEAEs of interest, EAIR/100 PY (95% CI)				
Serious infections	1.0 (0.7, 1.4)	1.2 (0.9, 1.5)	1.4 (0.9, 2.0)	1.1 (0.7, 1.7)	1.2 (0.9, 1.6)
Active tuberculosis	0.0	0.0	0.0	0.0	0.0
Fungal infections	20.1 (18.4, 22.0)	16.6 (15.3, 18.1)	25.0 (22.6, 27.6)	12.6 (10.9, 14.4)	16.7 (15.3, 18.3)
Oral candidiasis	12.6 (11.3, 14.0)	10.2 (9.1, 11.3)	15.9 (14.1, 17.9)	7.1 (5.9, 8.5)	10.1 (9.1, 11.3)
Inflammatory bowel disease	0.1 (0.0, 0.3)	0.1 (0.0, 0.3)	0.2 (0.0, 0.4)	0.1 (0.0, 0.4)	0.1 (0.0, 0.3)
Adjudicated MACE	0.5 (0.3, 0.8)	0.6 (0.4, 0.8)	0.7 (0.4, 1.1)	0.5 (0.2, 0.9)	0.6 (0.4, 0.9)
Malignancies	0.8 (0.5, 1.2)	0.9 (0.6, 1.2)	0.6 (0.3, 1.1)	1.2 (0.7, 1.8)	0.9 (0.6, 1.2)
NMSC	0.3 (0.2, 0.6)	0.3 (0.2, 0.6)	0.3 (0.1, 0.7)	0.3 (0.1, 0.7)	0.3 (0.2, 0.5)
Adjudicated SIB	0.0 (0.0, 0.2)	0.1 (0.0, 0.2)	0.1 (0.0, 0.4)	0.1 (0.0, 0.3)	0.1 (0.0, 0.2)
Neutropenia events	0.8 (0.6, 1.2)	0.6 (0.4, 0.9)	0.8 (0.4, 1.3)	0.2 (0.0, 0.5)	0.4 (0.3, 0.7)
Hepatic events	4.3 (3.6, 5.2)	4.0 (3.4, 4.7)	3.7 (2.9, 4.7)	3.2 (2.5, 4.1)	3.2 (2.7, 3.8)
AST or ALT elevations ^b	I		 		
>3x ULN	2.4 (1.9, 3.0)	2.2 (1.7, 2.7)	2.8 (2.1, 3.6)	1.9 (1.3, 2.6)	2.1 (1.7, 2.6)
>5x ULN ^c	0.8 (0.5, 1.2)	0.6 (0.4, 0.9)	0.7 (0.4, 1.2)	0.5 (0.2, 0.9)	0.6 (0.4, 0.9)
Serious hypersensitivity reactions ^d	0.2 (0.1, 0.4)	0.1 (0.0, 0.3)	0.2 (0.0, 0.4)	0.1 (0.0, 0.3)	0.1 (0.0, 0.3)
Injection site reactions	2.3 (1.8, 2.9)	1.9 (1.5, 2.3)	2.7 (2.0, 3.5)	1.2 (0.8, 1.8)	1.8 (1.4, 2.3)


ata are shown as of the data cut-off (two years: 9 Nov 2020; three years: 23 Oct 2021). ^aPatients are included in the relevant BKZ dose group based on the dose most recently received prior to the date of the adverse event or assessment. Patients who received both BKZ 320 mg Q4W and Q8W are included in the population count of both treatment groups, but only once in each BKZ Total group; Not all hepatic laboratory parameter elevations were reported as adverse events; >3x and >5x elevations are evaluated independently, hence patients with >5x elevations are also included in the >3x data; 4No anaphylactic reactions associated with BKZ were reported

Kenneth B. Gordon,¹ Richard G. Langley,² Richard B. Warren,³ Yukari Okubo,⁴ David Rosmarin,⁵ Mark Lebwohl,⁶ Luke Peterson,⁷ Cynthia Madden,⁷ Dirk de Cuyper,⁸ Natalie Nunez Gomez,⁹ Diamant Thaçi¹⁰

Summary of treatment exposure, summary of TEAEs, most common TEAEs, and TEAEs of interest in BKZ-treated patients in the phase 2 and 3 trials

Figure 1 Cumulative EAIRs for TEAEs over three

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BKZ: bimekizumab; CI: confidence interval; EAIR: exposure-adjusted incidence rate; IL-17: interleukin-17; MACE: major adverse cardiac event; NMSC: non-melanoma skin cancer; OLE: open-label extension; PY: patient-years; Q4W: every 8 weeks; SD: standard deviation; SIB: suicidal ideation and behavior; TEAE: treatment-emergent adverse event; TMF: tumour necrosis factor; ULN: upper limit of normal



Treatment period

Error bars represent 95% CIs. Data are pooled from four phase 2 and four phase 3 trials. Phase 2 data were not collected beyond 2 years. Data are reported as of the relevant data cut-offs: ^a1 Nov 2019; ^b9 Nov 2020; ^c23 Oct 202

Conclusions

BKZ was well-tolerated over three years of treatment; no safety signals were identified. EAIRs of TEAEs did not increase compared with data from two years of treatment.⁴



